A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to demonstrate a pharmacodynamic effect of CK 2017357
on measures of skeletal muscle function or fatigability in patients with ALS.